Novo Nordisk expects phase III data for diabetes app imminently
In just a few weeks, Novo Nordisk will receive data from a phase III study in which the pharmaceutical company’s own app, Doseguide, played an important role, Executive Vice President for Development at Novo Nordisk Martin Holst Lange tells MedWatch.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app